bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing. Through its VITEK, VIDAS and BIOFIRE systems, bioMérieux provides rapid, accurate results that support clinical decision-making and infection control.
Founded in 1963 by Dr. Alain Mérieux, bioMérieux has grown from a small French laboratory into a multinational corporation still guided by the Mérieux family. The company maintains a strong commitment to innovation, investing in research and development to address emerging health threats such as antibiotic resistance and global infectious disease outbreaks. Leadership continuity is provided by members of the Mérieux family, who serve on the board and executive team, ensuring that the company’s strategic direction remains aligned with its founding mission of advancing public health through diagnostics.
With headquarters in Marcy-l’Étoile, France, bioMérieux operates a network of subsidiaries, production sites and research centers across more than 160 countries. The company’s global footprint includes major facilities in Europe, North America and Asia-Pacific, enabling efficient manufacturing, regulatory compliance and customer support worldwide. By partnering with hospitals, laboratories and food and beverage companies, bioMérieux sustains a diverse customer base and continues to expand its presence in emerging markets, contributing to improved health outcomes and safety standards around the world.
AI Generated. May Contain Errors.
Free BMXMF Stock Alerts